Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1245/s10434-024-16820-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ASO Author Reflections: CD45RO-Positive Memory T Cell Density in the Tumoral Core and Invasive Margin as an Immune-Related Prognostic Marker in Esophageal Squamous Cell Carcinoma.
Ann Surg Oncol
January 2025
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita City, Osaka, Japan.
ASO Visual Abstract: Ultrasound Visualization of the Recurrent Laryngeal Nerve-A Prospective Clinical Validation Study.
Ann Surg Oncol
January 2025
Department of Ultrasound, Peking University Third Hospital, Beijing, China.
Discovery and characterization of stereodefined PMO-gapmers targeting tau.
Mol Ther Nucleic Acids
March 2025
Eisai Inc., 35 Cambridgepark Drive, Cambridge, MA 02140, USA.
Antisense oligonucleotides (ASOs) are an important class of therapeutics to treat genetic diseases, and expansion of this modality to neurodegenerative disorders has been an active area of research. To realize chronic administration of ASO therapeutics to treat neurodegenerative diseases, new chemical modifications that improve activity and safety profiles are still needed. Furthermore, it is highly desirable to develop a single stereopure ASO with a defined activity and safety profile to avoid any efficacy and safety concerns due to the batch-to-batch variation in the composition of diastereomers.
View Article and Find Full Text PDFPrognostic Significance of Lymphocyte-to-Monocyte Ratio in Patients With Unresectable Biliary Tract Cancer Undergoing Systemic Chemotherapy.
Cancer Diagn Progn
January 2025
Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan.
Background/aim: The incidence of biliary tract cancers (BTC), including cholangiocarcinoma and gallbladder cancer, has been increasing worldwide. Approximately 70% of BTC patients have advanced disease at diagnosis, leading to a poor survival rate. Recent clinical trials have demonstrated that the addition of immune checkpoint inhibitors, such as durvalumab or pembrolizumab, to gemcitabine plus cisplatin chemotherapy significantly improves survival rates, making triple therapy the current standard for first-line treatment of BTC.
View Article and Find Full Text PDFASO Author Reflections: Impact of Primary Tumor Size in Thymic Epithelial Tumor.
Ann Surg Oncol
January 2025
Division of Hematology Oncology, Penn State College of Medicine, Hershey, PA, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!